Android app on Google Play

Barclays Remains Bullish on Vertex (VRTX); Upside to Phase I Data

May 25, 2012 1:40 PM EDT Send to a Friend
Get Alerts VRTX Hot Sheet
Price: $64.17 -0.34%

Rating Summary:
    19 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 9 | New: 22
Trade VRTX Now!
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Vertex (NASDAQ: VRTX) price target of $77.00.

Analyst, Ying Huang, said, "We remain bullish as we see upside from Phase I data of the Alios nucleotide HCV polymerase inhibitors (nucs). Next key catalyst lies in the data of Kalydeco/VX-809 in cystic fibrosis patients with heterozygous F508del mutation in July."

Huang thinks Vertex's nucs are similar to the Gilead (Nasdaq: GILD) / Bristol Myers (NYSE: BMY) nucs in structure.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $64.09 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Barclays

Add Your Comment